Suppr超能文献

相似文献

3
Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation.
Metabolism. 2024 May;154:155818. doi: 10.1016/j.metabol.2024.155818. Epub 2024 Feb 17.
4
Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking.
Circulation. 2019 Jun 11;139(24):2765-2777. doi: 10.1161/CIRCULATIONAHA.119.039610. Epub 2019 Mar 26.
5
Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart.
Circulation. 2021 May 4;143(18):1797-1808. doi: 10.1161/CIRCULATIONAHA.120.052671. Epub 2021 Feb 19.
6
Ketones can become the major fuel source for the heart but do not increase cardiac efficiency.
Cardiovasc Res. 2021 Mar 21;117(4):1178-1187. doi: 10.1093/cvr/cvaa143.
10
Metabolic efficiency promotes protection from pressure overload in hearts expressing slow skeletal troponin I.
Circ Heart Fail. 2015 Jan;8(1):119-27. doi: 10.1161/CIRCHEARTFAILURE.114.001496. Epub 2014 Nov 25.

引用本文的文献

1
Hyperpolarized [1-C] pyruvate MRSI reveals a diet-dependent metabolic shift in ZSF1 rats.
J Magn Reson Open. 2025 Sep;24. doi: 10.1016/j.jmro.2025.100205. Epub 2025 Jun 30.
2
Ketone Bodies in Cardiovascular Disease: The Vasculature as a Therapeutic Target.
JACC Basic Transl Sci. 2025 Jul 17;10(8):101328. doi: 10.1016/j.jacbts.2025.101328.
3
Cardiac substrate metabolism in type 2 diabetes.
Biochem J. 2025 May 21;482(10):499-518. doi: 10.1042/BCJ20240189.
4
Ketone Body Induction: Insights into Metabolic Disease Management.
Biomedicines. 2025 Jun 16;13(6):1484. doi: 10.3390/biomedicines13061484.
5
Safety and efficacy of adjuvant Sotagliflozin therapy in patients with T1D - an update and systematic review and meta-analysis.
Front Endocrinol (Lausanne). 2025 Jun 3;16:1506652. doi: 10.3389/fendo.2025.1506652. eCollection 2025.
6
Characteristics of Cardiac Ketone Body Metabolism Throughout the Life Cycle.
Cardiovasc Ther. 2025 May 25;2025:5913327. doi: 10.1155/cdr/5913327. eCollection 2025.
7
Decoding the Liver-Heart Axis in Cardiometabolic Diseases.
Circ Res. 2025 May 23;136(11):1335-1362. doi: 10.1161/CIRCRESAHA.125.325492. Epub 2025 May 22.
10
Partial Regulation of Ketone Metabolism by Hypoxia in H9C2 Cardiomyocytes.
Curr Med Sci. 2025 Feb;45(1):25-34. doi: 10.1007/s11596-025-00002-w. Epub 2025 Feb 20.

本文引用的文献

1
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.124079.
3
The effects of the ketone body β-hydroxybutyrate on isolated rat ventricular myocyte excitation-contraction coupling.
Arch Biochem Biophys. 2019 Feb 15;662:143-150. doi: 10.1016/j.abb.2018.11.027. Epub 2018 Dec 10.
4
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587. doi: 10.1016/j.jacbts.2018.07.006. eCollection 2018 Oct.
5
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
JACC Basic Transl Sci. 2017 Aug 4;2(4):347-354. doi: 10.1016/j.jacbts.2017.07.003. eCollection 2017 Aug.
6
Loss of Metabolic Flexibility in the Failing Heart.
Front Cardiovasc Med. 2018 Jun 6;5:68. doi: 10.3389/fcvm.2018.00068. eCollection 2018.
7
Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism.
JCI Insight. 2018 May 17;3(10). doi: 10.1172/jci.insight.99239.
8
Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice.
Eur J Pharmacol. 2018 Jun 15;829:121-128. doi: 10.1016/j.ejphar.2018.04.019. Epub 2018 Apr 19.
9
Cardiac-Specific Deletion of Pyruvate Dehydrogenase Impairs Glucose Oxidation Rates and Induces Diastolic Dysfunction.
Front Cardiovasc Med. 2018 Mar 6;5:17. doi: 10.3389/fcvm.2018.00017. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验